KR20100125742A - Cosmetic composition containing extract of magnolia officinalis for reducing accumulation of lipid - Google Patents
Cosmetic composition containing extract of magnolia officinalis for reducing accumulation of lipid Download PDFInfo
- Publication number
- KR20100125742A KR20100125742A KR1020090044589A KR20090044589A KR20100125742A KR 20100125742 A KR20100125742 A KR 20100125742A KR 1020090044589 A KR1020090044589 A KR 1020090044589A KR 20090044589 A KR20090044589 A KR 20090044589A KR 20100125742 A KR20100125742 A KR 20100125742A
- Authority
- KR
- South Korea
- Prior art keywords
- water
- cosmetic composition
- extract
- fat accumulation
- cells
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 238000009825 accumulation Methods 0.000 title claims abstract description 39
- 239000000203 mixture Substances 0.000 title claims abstract description 29
- 239000002537 cosmetic Substances 0.000 title claims abstract description 26
- 241001673966 Magnolia officinalis Species 0.000 title abstract description 6
- 150000002632 lipids Chemical class 0.000 title abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000006071 cream Substances 0.000 claims abstract description 5
- 238000001914 filtration Methods 0.000 claims abstract description 5
- -1 pack Substances 0.000 claims abstract description 4
- 239000000686 essence Substances 0.000 claims abstract description 3
- 239000006260 foam Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000002674 ointment Substances 0.000 claims abstract description 3
- 239000000344 soap Substances 0.000 claims abstract description 3
- 239000007921 spray Substances 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 8
- 241000219122 Cucurbita Species 0.000 claims description 7
- 235000009852 Cucurbita pepo Nutrition 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 4
- 238000005119 centrifugation Methods 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000001629 suppression Effects 0.000 claims 1
- 230000014509 gene expression Effects 0.000 abstract description 33
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 abstract description 24
- 108010013563 Lipoprotein Lipase Proteins 0.000 abstract description 17
- 102000016267 Leptin Human genes 0.000 abstract description 15
- 108010092277 Leptin Proteins 0.000 abstract description 15
- 229940039781 leptin Drugs 0.000 abstract description 15
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 abstract description 15
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 abstract description 10
- 108020004999 messenger RNA Proteins 0.000 abstract description 8
- 239000006228 supernatant Substances 0.000 abstract description 4
- 238000003809 water extraction Methods 0.000 abstract description 2
- 102100022119 Lipoprotein lipase Human genes 0.000 abstract 2
- 102000023984 PPAR alpha Human genes 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 description 39
- 210000004027 cell Anatomy 0.000 description 39
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 27
- 230000004069 differentiation Effects 0.000 description 26
- 108090000623 proteins and genes Proteins 0.000 description 19
- 108010016731 PPAR gamma Proteins 0.000 description 16
- 102000012132 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 16
- 102000043296 Lipoprotein lipases Human genes 0.000 description 14
- 102000000019 Sterol Esterase Human genes 0.000 description 14
- 108010055297 Sterol Esterase Proteins 0.000 description 14
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 230000003833 cell viability Effects 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- VVOAZFWZEDHOOU-UHFFFAOYSA-N magnolol Chemical compound OC1=CC=C(CC=C)C=C1C1=CC(CC=C)=CC=C1O VVOAZFWZEDHOOU-UHFFFAOYSA-N 0.000 description 7
- 102100026189 Beta-galactosidase Human genes 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- BYTORXDZJWWIKR-UHFFFAOYSA-N Hinokiol Natural products CC(C)c1cc2CCC3C(C)(CO)C(O)CCC3(C)c2cc1O BYTORXDZJWWIKR-UHFFFAOYSA-N 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 108090001061 Insulin Proteins 0.000 description 5
- FVYXIJYOAGAUQK-UHFFFAOYSA-N honokiol Chemical compound C1=C(CC=C)C(O)=CC=C1C1=CC(CC=C)=CC=C1O FVYXIJYOAGAUQK-UHFFFAOYSA-N 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 4
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 235000021588 free fatty acids Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 235000014443 Pyrus communis Nutrition 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000024245 cell differentiation Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 210000002510 keratinocyte Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 210000000229 preadipocyte Anatomy 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000030914 Fatty Acid-Binding Human genes 0.000 description 2
- 102000057621 Glycerol kinases Human genes 0.000 description 2
- 108700016170 Glycerol kinases Proteins 0.000 description 2
- 108010008604 L-alpha-glycerol-phosphate oxidase Proteins 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 108091022862 fatty acid binding Proteins 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229940116257 pepper extract Drugs 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- ROPDWYIWHWKVLI-UHFFFAOYSA-N 4-prop-2-enyl-2-(4-prop-2-enylphenoxy)phenol Chemical compound OC1=CC=C(CC=C)C=C1OC1=CC=C(CC=C)C=C1 ROPDWYIWHWKVLI-UHFFFAOYSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- 102100030497 Cytochrome c Human genes 0.000 description 1
- 108010075031 Cytochromes c Proteins 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- SNYVPSXUTGEODU-UHFFFAOYSA-N Isomagnolol Natural products OC1=CC=C(CC=C)C=C1OC1=CC=CC(CC=C)=C1 SNYVPSXUTGEODU-UHFFFAOYSA-N 0.000 description 1
- YKGCBLWILMDSAV-GOSISDBHSA-N Isoxanthohumol Natural products O(C)c1c2C(=O)C[C@H](c3ccc(O)cc3)Oc2c(C/C=C(\C)/C)c(O)c1 YKGCBLWILMDSAV-GOSISDBHSA-N 0.000 description 1
- 108010067028 Mitochondrial Permeability Transition Pore Proteins 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000012083 RIPA buffer Substances 0.000 description 1
- 108050002653 Retinoblastoma protein Proteins 0.000 description 1
- 230000018199 S phase Effects 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- XFIOKOXROGCUQX-UHFFFAOYSA-N chloroform;guanidine;phenol Chemical compound NC(N)=N.ClC(Cl)Cl.OC1=CC=CC=C1 XFIOKOXROGCUQX-UHFFFAOYSA-N 0.000 description 1
- 210000004922 colonic epithelial cell Anatomy 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- FUSADYLVRMROPL-UHFFFAOYSA-N demethylxanthohumol Natural products CC(C)=CCC1=C(O)C=C(O)C(C(=O)C=CC=2C=CC(O)=CC=2)=C1O FUSADYLVRMROPL-UHFFFAOYSA-N 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 150000002185 fatty acyl-CoAs Chemical class 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- SYJRVVFAAIUVDH-UHFFFAOYSA-N ipa isopropanol Chemical compound CC(C)O.CC(C)O SYJRVVFAAIUVDH-UHFFFAOYSA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001008 quinone-imine dye Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001718 repressive effect Effects 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- VLRNWUFGTCSJDO-UHFFFAOYSA-N trans-Isomagnolol Natural products CC=CC1=CC=C(O)C(C=2C(=CC=C(C=CC)C=2)O)=C1 VLRNWUFGTCSJDO-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- ORXQGKIUCDPEAJ-YRNVUSSQSA-N xanthohumol Chemical compound COC1=CC(O)=C(CC=C(C)C)C(O)=C1C(=O)\C=C\C1=CC=C(O)C=C1 ORXQGKIUCDPEAJ-YRNVUSSQSA-N 0.000 description 1
- UVBDKJHYMQEAQV-UHFFFAOYSA-N xanthohumol Natural products OC1=C(CC=C(C)C)C(OC)=CC(OC)=C1C(=O)C=CC1=CC=C(O)C=C1 UVBDKJHYMQEAQV-UHFFFAOYSA-N 0.000 description 1
- 235000008209 xanthohumol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/044—Suspensions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
- A61K8/064—Water-in-oil emulsions, e.g. Water-in-silicone emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dispersion Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 지방축적 억제용 화장료 조성물에 관한 것으로, 더욱 상세하게는 후박추출물을 함유하는 지방축적 억제용 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition for inhibiting fat accumulation, and more particularly, to a cosmetic composition for inhibiting fat accumulation containing thick extract.
비만은 세계 각국에서 증가추세에 있는 심각한 보건문제로 인식되고 있으며 우리나라 역시 고도의 산업성장과 세계화의 영향으로, 식생활 패턴의 서구화 및 신체 활동량 부족이 급속히 진행되어 비만 인구가 현저히 증가하고 있다. 또한, 현재 우리나라의 주요 사망원인인 순환기계 질환, 암, 당뇨병 등이 비만과 밀접한 관련이 있어 그 심각성이 더욱 고조되고 있는 실정이다.Obesity is recognized as a serious health problem that is on the rise in many countries around the world, and Korea is also affected by high industrial growth and globalization. In addition, circulatory disease, cancer, diabetes, etc., which are the major causes of death in Korea, are closely related to obesity.
지방 조직(adipose tissue)은 에너지를 저장하는 기관으로, 음식물 섭취 등으로 인해 과도하게 섭취된 에너지를 이용하여 트리글리세라이드(triglyceride)를 형성한다. 트리글리세라이드(Triglyceride)는 'chylomicrons'과 VLDL(very low- density lipoprotein ) 입자를 통해 이동하며 'extracellular lipoprotein lipase'에 의해 가수분해되어 글리세롤(glycerol)과 유리지방산(free fatty acid; FFA)을 생성한다. 또한, FFA는 지방세포(adipocytes)에 의해 'fatty acyl-CoA'로 변환되어 글리세롤-3-포스페이트(glycerol-3-phosphate)와 함께 세포 내에 트리글리세라이드(triglyceride)를 형성하는 과정으로 순환된다(P. B. Snyder, J. M. Esselstyn, K. Loughney, S. L. Wolda, and V. A. Florio, The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J. LipidRes.,46,494(2005)). 이러한 지방 조직은 정상 성인의 총 몸무게의 15- 20%를 차지하며, 신체에 널리 분포되어 있다(D. S. Gray. Diagnosis and prevalence of obesity. Med . Clin . NorthAm.,73,1(1989)). Adipose tissue is an organ that stores energy, and forms triglycerides using energy excessively ingested due to food intake. Triglycerides travel through 'chylomicrons' and very low-density lipoprotein (VLDL) particles and are hydrolyzed by 'extracellular lipoprotein lipase' to produce glycerol and free fatty acids (FFAs). . In addition, FFA is converted into 'fatty acyl-CoA' by adipocytes and circulated in the process of forming triglyceride in the cell together with glycerol-3-phosphate (PB). Snyder, JM Esselstyn, K. Loughney, SL Wolda, and VA Florio, The. role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J. LipidRes, 46, 494 (2005)). These adipose tissues account for 15-20% of the total weight of normal adults and are widely distributed in the body (DS Gray. Diagnosis and prevalence of obesity. Med . Clin . North Am ., 73 , 1 (1989)).
최근, 지방 세포 내의 수많은 유전자 및 단백질의 발현 변화에 대한 연구가 많이 진행되고 있으며 대표적인 지방분화 촉진에 관여하는 전사인자들로 PPAR-γ(peroxisome proliferator activated receptor γ)와 C/EBP α(CCAAT-enhancer binding protein α) 등이 있는데, 이는 지방세포를 성숙하게 하고 지질대사에 관여하는 유전자를 자극하여 지방 축적에 관여한다(X. Guo, L. Kan. Analysis gene expression profile during 3T3-L1 preadipocyte differentiation. Gene . 251,45(2000)). Recently, many studies on expression changes of numerous genes and proteins in adipocytes have been conducted. Representative transcription factors involved in promoting fat differentiation are PPAR-γ (peroxisome proliferator activated receptor γ) and C / EBP α (CCAAT-enhancer). There are such α binding protein), which stimulates the gene involved in lipid metabolism and mature fat cells involved in fat accumulation (X. Guo, L. Kan. Analysis gene expression profile during 3T3-L1 preadipocyte differentiation. gene 251, 45 (2000)).
PPARs는 핵수용체(nuclear hormone receptor) 슈퍼페밀리(superfamily)에 속하며, 특히 PPAR-γ는 PPAR-γ1과 PPAR-γ2의 두 가지 아형(isoform)으로 이루어져 있으며 PPAR-γ2는 PPAR-γ1에 비해 'N-terminal' 부분에 30개의 아미노산을 더 포 함한다. 지방세포에는 주로 PPAR-γ2가 더 많이 존재하며 PPAR-γ1은 지방세포와 대식세포(macrophage), 대장상피세포 등 다양한 세포에 적은 양으로 존재한다. 지방세포에서 PPAR-γ은 지방세포 특이적인 지방산 바인딩 프로테인(fatty acid binding protein)인 aP2 뿐만 아니라 많은 유전자들의 발현을 유도한다. PPARs belong to the nuclear hormone receptor superfamily, in particular PPAR-γ consists of two isoforms, PPAR-γ1 and PPAR-γ2, and PPAR-γ2 is a 'N' as compared to PPAR-γ1. The term 'terminal' contains 30 more amino acids. Adipose cells mainly contain more PPAR-γ2, and PPAR-γ1 is present in a small amount in various cells such as adipocytes, macrophages, and colonic epithelial cells. In adipocytes, PPAR-γ induces the expression of many genes as well as aP2, a fat cell-specific fatty acid binding protein.
3T3-L1 지방 전구세포는 1-메틸-3-이소부틸-잔틴(1-methyl-3-isobutyl- xanthine), 데사메타손(dexamethasone) 과 인슐린(insulin) (MDI)을 처리하여 배양하면 G1에서 S기로 진입하여 분화가 시작되는데 그 조절자로 Rb(retinoblastoma protein)가 작용하여 C/EBPs에 결합된다. C/EBPs는 지방세포의 분화에 있어서 중요한 전사인자로서 다이머(dimer)를 형성할 수 있는 기능을 가진 'leucine -zipper' 결합부위와 DNA 결합부위를 가지고 있다(T. Mosmann, Rapid colorimetric assay for the cellular growth and survival : application to proliferation and cytotoxic assay,J.Immun.Methods.,65,55(1983)). MDI를 배지에 첨가하여 지방세포로의 분화를 유도시키면 4시간 이내에 C/EBPβ와 C/EBPα가 유도되어 헤테로다이머(heterodimer)를 이루게 되어 PPAR-γ(peroxisome proliferator- activated receptor γ) 와 C/EBPα를 활성화시켜 아딥신(adipsine), aP2(adipocyte-specific fatty acid binding protein), 렙틴(leptin) 등과 같은 지방 세포 특이 유전자들을 활성화 시킨다(Z. Cao, R. M. Umek, and S. L. McKnight, Regulated expression of three C/EBP isoforms during aipose conversion of 3T3-L1 cells. GenesDev.,5(9),1538(1991), W. C. Yeh, Z. Cao, M. Classon, and S. L. McKnight, Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP familly of leucine zipper proteins. GenesDev.,9(2), 168(1995), Q. Q. Tang, M. S. Jiang, and M. D. Lane, Repressive effect of Sp1 on the C/EBPα gene promoter: Role in adipocyte differentiation. Mol . Cell . Biol.,19(7), 4855(1999)).3T3-L1 adipocytes were cultured by treatment with 1-methyl-3-isobutyl-xanthine, desamethasone and insulin (MDI). Differentiation is initiated by entering the S phase, and Rb (retinoblastoma protein) acts as a regulator and binds to C / EBPs. C / EBPs have a 'leucine-zipper' binding site and a DNA binding site, which are important transcription factors for differentiation of adipocytes (D. Mosmann, Rapid colorimetric assay for the cellular growth and survival: application to proliferation and cytotoxic assay, J. Immun . Methods ., 65 , 55 (1983). When MDI was added to the medium to induce differentiation into adipocytes, C / EBP and C / EBPa were induced within 4 hours to form a heterodimer, resulting in PPAR-γ (peroxisome proliferator-activated receptor γ) and C / EBPa. Activation of adipocyte-specific genes such as adipsine, adipocyte-specific fatty acid binding protein (aP2), leptin (Z. Cao, RM Umek, and SL McKnight, Regulated expression of three C / EBP isoforms during aipose conversion of 3T3-L1 cells.Genes Dev ., 5 (9), 1538 (1991), WC Yeh, Z. Cao, M. Classon, and SL McKnight, Cascade regulation of terminal adipocyte differentiation by three members of the .. C / EBP familly of leucine zipper proteins GenesDev, 9 (2), 168 (1995), QQ Tang, MS Jiang, and MD Lane, Repressive effect of Sp1 on the C / EBPα gene promoter:. Role in adipocyte differentiation Mol . Cell. Biol., 19 ( 7), 4855 (1999)).
한편, 후박(Magnolia officinalis)은 쌍떡잎 식물에 속하여 미나리아재비목 녹나무과의 상록 활엽수로 한국, 일본, 타이완, 중국 남부에 서식한다. 예로부터 약용으로 줄기 및 가지의 껍질이 천식과 위장병 치료에 사용되었으며 마그놀(magnolol), 이소마그놀(isomagnolol), 호노키올(honokiol), 마치올(machiol)과 같은 성분이 함유되어 있다. 이 중, 호노키올(honokiol)은 폴리페놀(polyphenol)에 속하는 물질로 항우울, 혈전응고 저해, 신경 안정, 항균 효능을 나타내는 유용한 물질로 이용되고 있다. 최근, 호노키올(honokiol)이 다양한 암세포의 'mitochondrial permeability transition pore'의 유발(induction)과 시토크롬 c 방출(cytochrome c release), 카스파아제(caspase)의 활성화를 통해 세포 괴사가 유도하는 효능을 나타냄이 보고된 바 있다(J. Y. Yang, M. A. DellaFera, S. Rayalam and C. A. Baile, Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes. Obesity,16(6),1232 (2008)). On the other hand, Magnolia officinalis ) is a dicotyledonous plant, an evergreen broad-leaved tree of the genus Asteraceae, inhabiting Korea, Japan, Taiwan and southern China. For medicinal purposes, stem and branch bark has been used for the treatment of asthma and gastrointestinal diseases and contains components such as magnolol, isomagnolol, honokiol and machiol. Among these, honokiol (honokiol) is a polyphenol (polyphenol) belonging to a useful substance that exhibits antidepressant, antithrombotic inhibition, nerve stability, antibacterial effect. Recently, honokiol has been shown to induce cell necrosis through induction of 'mitochondrial permeability transition pore' of various cancer cells, cytochrome c release, and caspase activation. (JY Yang, MA DellaFera, S. Rayalam and CA Baile, Enhanced effects of xanthohumol plus honokiol on apoptosis in 3T3-L1 adipocytes. Obesity , 16 (6), 1232 (2008)).
그러나, 후박 추출물의 세포 내 지방축적 억제 효과에 대한 연구는 아직 미미한 실정이다. However, studies on the inhibitory effect on the intracellular fat accumulation of the bakbak extract is still insignificant.
이에 본 발명은 실질적으로 지방축적 억제 효과를 발휘하는 후박 추출물을 유효성분으로 함유하는 지방축적 억제용 화장료 조성물을 제공하는데 그 목적이 있다. Accordingly, an object of the present invention is to provide a cosmetic composition for inhibiting fat accumulation, containing a thick extract extract having an effect of effectively inhibiting fat accumulation as an active ingredient.
상기의 목적을 달성하기 위해 본 발명은 후박 추출물을 함유하는 것을 특징으로 하는 지방축적 억제용 화장료 조성물을 제공한다.In order to achieve the above object, the present invention provides a cosmetic composition for inhibiting fat accumulation, comprising a thick extract.
이하, 본 발명의 과제 해결 수단에 대해 상세히 설명하고자 한다.Hereinafter, the problem solving means of the present invention will be described in detail.
본 발명은 지방축적 억제용 화장료 조성물을 제공하기 위해 반드시 후박 추출물을 유효성분으로 함유한다.The present invention necessarily contains a thick leaf extract as an active ingredient to provide a cosmetic composition for inhibiting fat accumulation.
본 실험예에서는 본 발명에 유효성분으로 함유되는 후박 추출물의 실질적인 지방축적 억제효과를 확인하기 위해 먼저, 후박 추출물에 의한 세포 생존률, 세포 내 지방축적 정도와 트리글리세라이드 함량을 측정하였는데, 그 결과, 세포독성을 나타내지 않으면서, 세포내 지방축적 정도가 감소함을 확인할 수 있었으며, 트리글리세라이드 함량이 후박추출물의에 대해 농도 의존적으로 감소하는 것을 확인할 수 있었다. In the present experimental example, first, in order to confirm the substantial fat accumulation inhibitory effect of the extract of the pear extract contained as an active ingredient, the cell viability, intracellular fat accumulation degree and triglyceride content by the pear extract were measured. Without toxicity, it was confirmed that the degree of intracellular fat accumulation was reduced, and the triglyceride content was reduced in a concentration-dependent manner to the thick extract.
그리고 상기와 같은 결과를 바탕으로 후박 추출물이 지방 세포로의 분화를 억제하여 지방의 생성을 감소시키거나, 지방 세포 내에 생성된 지방을 분해하여 글리세롤(glycerol)과 유리지방산(free fatty acid) 형성에 영향을 미치는지 확인하기 위해, 지방 분해 효소인 HSL(hormone sensitive lipase)의 단백질 발현 수준을 측정한 결과, 후박 추출물에 대해 농도의존적으로 증가하는 것을 확인할 수 있었다. 그리고, 지방 세포 분화와 관여된 인자인 PPAR-γ는 후박 추출물을 처리한 지방세포로 분화된 후의 세포에서 단백질 발현이 감소되는 것을 확인할 수 있었다. Based on the above results, the extract of habakkuk reduces the production of fat by inhibiting the differentiation into fat cells, or breaks down the fat produced in the fat cells to form glycerol and free fatty acid. In order to determine whether the effect, the protein expression level of the lipolytic enzyme (hormone sensitive lipase) HSL (hormone sensitive lipase) was measured, it was confirmed that the concentration-dependent increase in the extract. In addition, PPAR-γ, a factor involved in adipocyte differentiation, was confirmed to reduce protein expression in cells after differentiation into adipocytes treated with pleated extract.
이에 더 실질적인 지방축적 억제 효능을 확인하기 위해 지방세포로의 분화에 관여하는 유전자의 mRNA 발현 수준을 확인하였는데, 지방 세포로의 분화시에는 지방 전구세포에 대비하여 렙틴(leptin), PPAR-α, LPL의 mRNA 발현이 급증하였으나, 분화가 유도된 세포에 후박 추출물을 처리하였을 때는 발현 수준이 지방 전구세포의 수준으로 나타난 것으로 보아 지방 세포로의 분화가 억제된다는 것을 추론할 수 할 수 있었다. The mRNA expression level of genes involved in the differentiation of adipocytes was confirmed to confirm the actual fat accumulation inhibitory effect. When the differentiation into adipocytes, leptin, PPAR-α, and LPL were compared to adipocytes. MRNA expression of, but when the thick extract extracts were treated to cells induced differentiation, the expression level was shown to be the level of adipocytes, it can be inferred that the differentiation into adipocytes is suppressed.
한편, 본 발명의 유효성분인 후박 추출물은 바람직하게 지방축적 억제용 화장료 조성물에 10~100㎍/mL 함유되는 것이 좋은데, 세포독성이 없으면서도 지방축적 억제 효과를 발휘하기 때문이다. On the other hand, the thick extract of the active ingredient of the present invention preferably contains 10 to 100 µg / mL in the fat accumulation inhibitory cosmetic composition, because it exhibits a fat accumulation inhibitory effect without cytotoxicity.
한편, 후박 추출물은 바람직하게 건조된 후박 1 중량부에 대해 물 10~20중량부를 첨가하여 열수 추출을 한 후, 여과를 한 다음, 4200~4800rpm 으로 50~70분 동안 원심분리하여 수득한 상층액을 최대 1㎛ 크기로 감압 여과하여 수득된 된 것이 좋다.On the other hand, after extracting hot water by adding 10 to 20 parts by weight of water to 1 part by weight of dried flakes preferably dried, filtered and then the supernatant obtained by centrifugation at 4200 ~ 4800rpm for 50 to 70 minutes It is preferably obtained by filtration under reduced pressure up to a size of 1 μm.
한편, 본 발명의 지방축적 억제용 화장료 조성물의 제형은 특정한 종류에 한 정되는 것은 아니고, 통상적으로 화장료 조성물 업계에서 사용되는 제형이라면 무관하나, 바람직하게는 화장수, 젤, 수용성 리퀴드, 크림, 에센스, 수중유(O/W)형 및 유중수(W/O)형으로 이루어진 기초화장료 제형, 연고, 수중유형 및 유중수형 메이크업베이스, 파운데이션, 스킨커버, 페이스파우더, 투웨이케익로 이루어진 색조화장료 제형, 클렌징폼, 클렌징 크림, 클렌징 워터, 비누, 팩, 스프레이 중에서 선택되는 어느 하나인 것이 좋다. On the other hand, the formulation of the cosmetic composition for inhibiting fat accumulation of the present invention is not limited to a specific kind, and is generally used as long as it is a formulation used in the cosmetic composition industry, but preferably a lotion, gel, water-soluble liquid, cream, essence, Basic cosmetic formulation consisting of oil-in-water (O / W) and oil-in-water (W / O) type, ointment, oil-in-water and water-in-oil makeup base, foundation, skin cover, face powder, two-way cake formulation, cleansing It may be any one selected from foam, cleansing cream, cleansing water, soap, pack, and spray.
상기에서 살펴본 바와 같이 본 발명의 지방축적 억제용 화장료 조성물은 세포 내 축적된 지방 및 트리글리세라이드를 감소시키고, 지방을 분해하는 효소인 HSL의 단백질 발현을 증가시키면서, 지방 세포 분화와 관련된 인자인 PPAR-γ의 발현을 감소시킬 뿐만 아니라, 렙틴(leptin)과 PPAR-α및 LPL의 mRNA의 발현을 감소시키는 후박 추출물을 유효성분으로 함유함으로써 실질적인 지방축적을 억제하는 효과를 발휘한다.As described above, the fat accumulation inhibitory cosmetic composition of the present invention reduces the fat accumulated in cells and triglycerides, and increases the protein expression of HSL, an enzyme that breaks down fat, while PPAR- which is a factor related to fat cell differentiation. Not only reduces the expression of γ, but also contains a thick extract that reduces the expression of leptin, mRNA of PPAR-α and LPL as an active ingredient, thereby suppressing substantial fat accumulation.
또한, 본 발명은 천연물질을 함유함으로써 화학물질에 대한 소비자의 거부감을 감소시킬 수 있다. In addition, the present invention can reduce the consumer's rejection of chemicals by containing natural substances.
이하, 본 발명의 구성 및 작용에 대해 하기 실시예에서 더욱 상세히 설명하지만, 본 발명의 권리범위가 하기 실시예에만 한정되는 것은 아니고, 이와 등가의 기술적 사상의 변형까지를 포함한다.Hereinafter, the configuration and operation of the present invention will be described in more detail with reference to the following examples, but the scope of the present invention is not limited to the following examples, and includes modifications of equivalent technical spirit.
실시예Example 1: 후박 추출물 제조 1: thick pepper extract manufacturer
건조된 후박 200g을 분쇄하여 분말화한 후, 증류수 3L를 첨가하여 열수 추출을 수행하였다. 추출이 완료된 후, 부직포를 이용하여 1차 여과를 수행하고 4,500rpm에서 60분 동안 원심분리 하였다. 상층액을 회수하여 1㎛ 크기의 여과지를 이용하여 감압 여과하였다. 회수한 여과액을 감압 농축하여 후박 추출물 파우더를 얻었다.200 g of dried thick foil was pulverized and powdered, and then 3 L of distilled water was added to perform hot water extraction. After the extraction was completed, primary filtration was performed using a nonwoven fabric and centrifuged at 4,500 rpm for 60 minutes. The supernatant was recovered and filtered under reduced pressure using a 1 μm filter paper. The recovered filtrate was concentrated under reduced pressure to obtain a thick extract powder.
실험예Experimental Example 1: 후박 추출물에 의한 세포 생존율 측정 1: Determination of Cell Viability by Thick Extract
본 실험예 1에서는 상기 실시예 1에서 수득한 후박 추출물 파우더에 의한 세포 생존율 측정하였다. In Experimental Example 1, the cell viability of the thick extract powder obtained in Example 1 was measured.
실험에 사용된 세포는 'Human keratinocyte(HaCaT)'와 지방 전구세포인 3T3-L1(mouse embryonic fibroblast, preadipocyte)을 사용하였으며 HaCaT 세포의 경우에는 10 % FBS, 페니실린(penicillin; 100unit/ml), 스트렙토마이신(strptomycin ; 100 unit/ml)이 첨가된 DMEM(Dulbecco's modified Egale's medium) 배지로 5 % CO2, 37℃에서 배양하였으며, 3T3-L1 세포는 10% 우아혈청(bovine calf serum, penicillin; 100unit/ml), 스트렙토마이신(streptomycin ; 100unit/ml)이 첨가된 DMEM(Dulbecco's modified Egale's medium)으로 5% CO2, 37℃에서 배양하였다. 3T3- L1의 지방세포로의 분화는 100μM 3-이소부틸-1-메틸잔틴(3-isobutyl-1-methylxanthine), 250nM 덱사메타손(dexamethasone), 3.3μM D-비오틴(biotin), 1% BSA(bovine serum albumin), 10㎍/ml 인슐린 용액(insulin solution from bovine pancreas; MDI)과 10% FBS를 함유한 배지로 유도하였으며, 10 % FBS와 10 ㎍/ml 인슐린(insulin)을 함유한 DMEM 배지로 교체하여 주면서 분화 정도를 관찰하였다. 3-(4,5-다이메틸티아졸-2-yl)-2,5-다이페닐테트라졸리엄 브로마이드(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; MTT)) 정량은 'Mosmann[11]'의 방법을 변형하여 실시하였다. 실험에 사용된 세포로는 'Human keratinocyte(HaCaT)'과 지방 전구세포인 3T3-L1을 이용하였다. HaCaT와 3T3-L1을 1×104cells/well의 농도로 준비한 96-웰 프레이트에 후박 추출물을 농도별로 투여하여 CO2배양기에서 24시간 동안 배양하였다. MTT 용액(5mg/mL)을 첨가하고 4시간 후 배양액을 제거하고 100㎕ 엑시드-이소프로파놀(acid-isopropanol; 0.04N HCl in isopropanol)를 첨가한 후, 570 nm에서 'ELISA reader(VICTOR3, PerkinElmer, USA)'로 흡광을 측정하였다. HaCaT세포와 3T3-L1 세포에 후박 추출물을 농도별로 처리한 후, 농도 증가에 따른 세포 생존율에 미치는 영향을 측정하였다. The cells used in the experiment were 'Human keratinocyte (HaCaT)' and 3T3-L1 (mouse embryonic fibroblast (preadipocyte), adipose progenitor cells, and 10% FBS, penicillin (100 unit / ml), and Cultured at 5% CO 2 , 37 ° C in DMEM (Dulbecco's modified Egale's medium) with strictomycin (100 unit / ml), 3T3-L1 cells were treated with 10% bovine calf serum, penicillin; 100 unit / ml. ml) and streptomycin (100 units / ml) were added to DMEM (Dulbecco's modified Egale's medium) at 5% CO 2 at 37 ° C. Differentiation of 3T3-L1 into adipocytes was achieved with 100μM 3-isobutyl-1-methylxanthine, 250nM dexamethasone, 3.3μM D-biotin, 1% bovine serum albumin), 10 μg / ml insulin solution (insulin solution from bovine pancreas (MDI) and 10% FBS-containing medium, and 10% FBS and 10 μg / ml insulin (insulin) The degree of differentiation was observed while giving. 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide; MTT )) Quantification was performed by modifying the method of Mosmann [11]. The cells used in the experiment were 'Human keratinocyte (HaCaT)' and 3T3-L1 adipocytes. HaCaT and 3T3-L1 were prepared in a 96-well plate prepared at a concentration of 1 × 10 4 cells / well, followed by incubation for 24 hours in a CO 2 incubator. After 4 hours of adding MTT solution (5 mg / mL), the culture medium was removed, and 100 μl acid-isopropanol (0.04 N HCl in isopropanol) was added, followed by 'ELISA reader (VICTOR3, PerkinElmer) at 570 nm. , USA) 'was measured for absorption. HaCaT cells and 3T3-L1 cells were treated with thick extracts at different concentrations, and the effects on cell viability with increasing concentrations were measured.
후박 추출물에 의한 세포 생존율을 측정한 결과(도 1), HaCaT 세포의 경우에는 최고 시료 처리 농도인 200㎍/㎖에서 약 75%의 세포 생존율은 보였으며, 3T3-L1 세포의 경우에는 최고 시료 처리 농도인 200㎍/㎖에서도 92.2%의 세포 생존율을 나타내었다. As a result of measuring the cell viability by the extract of gourd (FIG. 1), about 75% of the cell viability was observed at 200 µg / ml of the highest sample concentration in HaCaT cells, and the highest sample treatment in the case of 3T3-L1 cells. The cell survival rate was 92.2% even at the concentration of 200 µg / ml.
상기의 결과로부터 HaCaT 세포와 3T3-L1 세포에 후박 추출물 10~100㎍/㎖ 를 처리하였을 때, 세포 생존율에 큰 영향을 미치지 않음을 확인하였다.From the above results, it was confirmed that when the HaCaT cells and the 3T3-L1 cells were treated with 10 ~ 100 µg / ml of the extract, the cell viability was not significantly affected.
실험예Experimental Example 2: 후박 추출물에 의한 지방축적 억제 효능 측정 2: Determination of Fat Accumulation Inhibition Effect by Hupak Extract
본 실험예 2에서는 상기 실시예 1에서 수득된 후박 추출물에 의한 지방축적 억제 효능을 측정하였다. In Experimental Example 2, the fat accumulation inhibitory effect of the thick gourd extract obtained in Example 1 was measured.
세포 내에 형성되는 지방의 축적 정도를 평가하는 방법으로 Oil- red O 염색을 수행하였다. 3T3-L1을 1×105cells/well의 농도로 준비하여 농도별로 후박 추출물을 처리하고 24시간 배양하였다. PBS로 각 웰을 세척하고 4% 파라포름알데하이드(paraformaldehyde)를 1ml씩 넣어 5분 동안 정치한 후, 제거하고 4% 파라포름알데하이드(paraformaldehyde)를 1ml씩 첨가하여 1시간 동안 실온에서 정치하였다. 파라포름알데하이드(paraformaldehyde)를 제거하고 60% 이소프로파놀(isopropanol)을 첨가하여 세척한 후, 각 웰이 완전히 마를 때까지 실온에 방치하였다. 건조된 각 웰에 'Oil red O working solution'을 1ml씩 넣고 1시간 동안 염색한 후, 증류수로 4회 반복하여 세척하였다. 세척한 웰이 완전히 마른 후에 100% 이소프로파놀(isopropanol)을 2ml씩 넣어 염색된 시약을 용출시켜 500nm에서 흡광을 측정하여 지방축적 정도를 평가하였다. 지방 전구 세포에 MDI를 처리하여 분화를 유도하여 지방세포로 전환된 3T3-L1에 후박 열수 추출물을 농도별로 처리한 후, 세포 내에 형성된 'lipid droplet'의 양을 간접적으로 측정하였다. Oil-Red O 시약은 'fat- soluble dye'로, 지방 세포로 분화된 3T3-L1 세포에 세포의 생존율에 거의 영향을 미치지 않는 농도인 50, 100㎍/㎖을 처리하여 세포 내에 형성된 지방(lipids)와 중성지방(neutral tirglycerides)를 Oil-Red O 시약으로 염색하고 이소프로파놀(isopropanol)로 회수한 후 흡광으로 확인하였다.Oil- red O staining was performed to evaluate the degree of fat accumulation in cells. 3T3-L1 was prepared at a concentration of 1 × 10 5 cells / well, treated with thick extracts by concentration, and incubated for 24 hours. Each well was washed with PBS, and 1 ml of 4% paraformaldehyde was added thereto and allowed to stand for 5 minutes. Then, the mixture was removed and 1 ml of 4% paraformaldehyde was added thereto and allowed to stand at room temperature for 1 hour. Paraformaldehyde was removed and washed with the addition of 60% isopropanol, and then allowed to stand at room temperature until each well was completely dry. 1 ml of 'Oil red O working solution' was added to each dried well for 1 hour, and then washed repeatedly with distilled water four times. After the washed wells were completely dried, 2 ml of 100% isopropanol was added and the stained reagents were eluted, and the absorbance was measured at 500 nm to evaluate the degree of fat accumulation. After treatment with the adipocyte MDI to induce differentiation, 3T3-L1 transformed into adipocytes was treated by concentration of thick thin water extract, and the amount of 'lipid droplet' formed in the cells was indirectly measured. Oil-Red O reagent is a 'fat-soluble dye'. Lipids formed in cells after treatment with 3T3-L1 cells differentiated into adipocytes at concentrations of 50 and 100 µg / ml have little effect on cell viability. ) And neutral fat (neutral tirglycerides) was stained with Oil-Red O reagent and recovered with isopropanol (isopropanol) and confirmed by absorption.
후박 추출물에 의한 지방축적 억제 효능 측정한 결과(도 2), 후박 추출물 50 ㎍/㎖에서 76%, 100㎍/㎖에서 78%의 세포 내 지방축적 억제 효능이 나타나는 것을 확인할 수 있었다. As a result of measuring fat accumulation inhibitory effect by hoobak extract (FIG. 2), it was confirmed that the inhibitory effect of intracellular fat accumulation inhibition of 76% at 50 ㎍ / ㎖, 78% at 100 ㎍ / ㎖ extract.
실험예Experimental Example 3: 후박 추출물에 의한 세포 내 3: intracellular by thick extract 트리글리세라이드Triglyceride (( TGTG ) 함량의 감소 정도 측정) Determination of the amount of decrease in content
본 실험예 3에서는 후박 추출물에 의한 세포 내 트리글리세라이드 함량의 감소 정도를 측정하였다. In Experimental Example 3, the degree of reduction of the intracellular triglyceride content by the extract of hoobac was measured.
3T3-L1 세포를 회수하여 1% 트립톤(Triton) X-100 이 함유된 PBS를 넣어 용해시켜 준비하고 TG의 농도는 GPO-tinder를 이용한, 'Serum Triglyceride Detection Kit(Sigma, TR0100, USA)'를 이용하여 측정하였다. 우선, TG 시약(TG reagent)에 10ml의 증류수를 넣고, 자유 글리세롤 시약(free glycerol reagent)에 40ml의 증류수를 각각 넣어주어 'reconstitute reagents'를 만든 후, 0.8ml의 프리 글리세롤 시약(free glycerol reagent)에 각각 10㎕ 물(water; blank), 10㎕ 글리세롤 스텐다드(glycerol standard; 2.5mg/ml standard), 10㎕ 샘플을 넣고 37 ℃에서 5분 동안 반응시키고 540nm에서 초기 흡광(IA)을 측정하였다. 그 후, 0.2 ml의 TG 시약(TG reagent)에 각각 10㎕ 물(water; blank), 10㎕ 글리세롤 스텐다드(glycerol standard; 2.5 mg/ml standard), 10㎕ 샘플을 넣고 37 ℃에서 5분 동안 반응시키고 540nm에서 최종 흡광(FA)을 측정하였다. TG의 양을 글리세롤(glycerol) 정량 곡선을 이용하여 계산하였다. 지방 세포로 분화가 유도된 3T3-L1 세포 내에 생성된 트리글리세라이드 함량(triglyceride contents) 측정은 효소학적 측정법을 이용하였다.3T3-L1 cells were collected and prepared by lysing PBS containing 1% Triton X-100, and the concentration of TG was obtained by using GPO-tinder, 'Serum Triglyceride Detection Kit (Sigma, TR0100, USA)'. Measured using. First, 10 ml of distilled water is added to TG reagent, 40 ml of distilled water is added to free glycerol reagent, respectively, to make 'reconstitute reagents', and then 0.8 ml of free glycerol reagent is used. 10 μl water (blank), 10 μl glycerol standard (2.5 mg / ml standard) and 10 μl sample were added thereto, and reacted at 37 ° C. for 5 minutes, and the initial absorbance (IA) was measured at 540 nm. Then, 10 μl water, 10 μl glycerol standard (2.5 mg / ml standard), and 10 μl sample were added to 0.2 ml of TG reagent (TG reagent) for 5 minutes at 37 ° C. And the final absorbance (FA) was measured at 540 nm. The amount of TG was calculated using a glycerol quantitative curve. Triglyceride contents produced in 3T3-L1 cells induced differentiation into adipocytes were measured by enzymatic assay.
세포 내에 존재하는 리포프로테인 리파아제(lipoprotein lipase)의 작용에 의하여 트리글리세라드(triglyceride)가 글리세롤(glycerol)과 유리지방산(free fatty acids)로 분해되게 된다. 분해된 글리세롤(glycerol)을 글리세롤 키나제(glycerol kinase; GK)와 글리세롤 포스페이트 옥시다아제(glycerol phosphate oxidase; GPO), 퍼옥시다아제(peroxidase) 등의 효소 반응에 의해 최종적으로 생성된 퀴논이민 염료(quinoneimine dye)를 흡광으로 확인하는 방법으로 후박 추출물에 의한 세포 내 트리글리세라이드(TG) 함량의 감소 정도 측정하였다. Triglyceride is broken down into glycerol and free fatty acids by the action of lipoprotein lipase present in cells. Decomposed glycerol is quinoneimine dye which is finally produced by an enzyme reaction such as glycerol kinase (GK), glycerol phosphate oxidase (GPO) and peroxidase. The degree of reduction of intracellular triglyceride (TG) content by thick extract was measured by the method of confirming by absorption.
후박 추출물에 의한 세포 내 트리글리세라이드(TG) 함량의 감소 정도를 측정한 결과(도 3), 후박 추출물의 농도가 증가함에 따라 세포 내의 트리글리세라이드 함량 수준이 감소하는 것을 확인할 수 있었고, 최고 시료 처리 농도인 100㎍/㎖에서 대조구(control) 대비 약 35 %의 트리글리세라이드 함량의 감소를 나타냈다.As a result of measuring the degree of decrease of intracellular triglyceride (TG) content by the thick gourd extract (Fig. 3), it was confirmed that the level of triglyceride content in the cell decreases as the concentration of the thick gourd extract was increased. At 100 μg / ml of phosphorus, a triglyceride content of about 35% was shown relative to the control.
상기의 결과로부터 본 발명의 지방축적 억제용 화장료 조성물이 지방 세포 내 지방축적을 감소시키는 사실을 추론할 수 있었다. From the above results, it can be inferred that the cosmetic composition for inhibiting fat accumulation of the present invention reduces fat accumulation in fat cells.
실험예Experimental Example 4: 후박 추출물이 4: thick pepper extract PPARPPAR -γ 및 -γ and HSLHSL 단백질 발현에 미치는 영향 측정 Measurement of impact on protein expression
본 실험예 4에서는 상기 실시예 1에서 수득한 후박 추출물이 PPAR-γ 및 HSL 단백질 발현에 미치는 영향을 측정하였다. In Experimental Example 4, the effect of the thick gourd extract obtained in Example 1 on the expression of PPAR-γ and HSL protein was measured.
상기 실험예 2 및 3에서 세포 내 지방축적 억제 효능과 트리글라세라이드 함량의 감소의 측정으로부터 후박 추출물이 세포 내 지방 생성을 억제하거나 지방 세포로의 분화를 억제한다는 사실을 추론할 수 있었는데, 이로부터 후박 추출물이 세포의 지방 분화 촉진과 관련된 단백질 발현과 연관성을 확인하기 위해 실험예 4를 실시하였다. From the measurement of the inhibition effect of intracellular fat accumulation and the reduction of triglyceride content in Experimental Examples 2 and 3, it could be inferred that the extract of gourd inhibits intracellular fat production or inhibits differentiation into adipocytes. Experimental Example 4 was carried out to confirm the correlation with the protein expression associated with promoting fat differentiation of cells.
지방 세포로 분화가 유도된 3T3-L1 세포에서 지방 분화 촉진에 관여하는 전사인자로 'peroxisome proliferator activated receptor-γ(이하 'PPAR-γ'라고 칭함)'와 'Hormone sensitive lipase(이하 'HSL'라고 칭함)' 등을 들 수 있는데, 본 실험예 4에서는 본 발명의 유효성분인 후박 추출물이 PPAR-γ와 HSL 단백질 발현에 미치는 영향을 측정하였다.In 3T3-L1 cells induced differentiation into adipocytes, the transcription factors involved in promoting the differentiation of 'peroxisome proliferator activated receptor-γ' (hereinafter referred to as' PPAR-γ ') and' Hormone sensitive lipase (hereinafter referred to as' HSL ') ), Etc. In this Experimental Example 4, the effect of the thick extract, which is the active ingredient of the present invention, on the expression of PPAR-γ and HSL protein was measured.
시료를 24 시간 처리한 3T3-L1 세포를 RIPA 버퍼(0.5% 소디움 디옥시콜레이트(sodium deoxycholate), 0.1% SDS, 1% NP-40, 1mM PMSF)로 용해하고 원심분리 하였다. 회수한 상층액을 12% SDS-PAGE를 이용하여 전기영동하고 이를 니트로셀룰로오스 멤브레인(nitrocellulose membrane)으로 옮겼다. 이를 5% 스킴 밀크(skim milk)가 함유된 트리스(Tris) 완충용액에서 PPAR-γ(sc-7273), HSL(sc-74489), β-actin(sc-1615) 항체와 각각 반응시킨 후, 2차 HRP-항체를 가하고 'WEST-ZOL western blotting detection system(chemiluminescence reagernt, Intron. Korea)' 을 사용하여 'Kodak X-ray film'에 감광시킨 후 현상하였다. Samples were treated for 24 hours and 3T3-L1 cells were lysed with RIPA buffer (0.5% sodium deoxycholate, 0.1% SDS, 1% NP-40, 1 mM PMSF) and centrifuged. The recovered supernatant was electrophoresed using 12% SDS-PAGE and transferred to a nitrocellulose membrane. This was reacted with PPAR-γ (sc-7273), HSL (sc-74489), and β-actin (sc-1615) antibodies in Tris buffer solution containing 5% skim milk, respectively. Secondary HRP-antibody was added and subjected to photodevelopment on 'Kodak X-ray film' using 'WEST-ZOL western blotting detection system (chemiluminescence reagernt, Intron. Korea)'.
후박 추출물이 PPAR-γ 및 HSL 단백질 발현에 미치는 영향 측정한 결과(도 4 및 도 5), 후박 추출물의 농도가 증가함에 따라 HSL의 단백질 발현이 대조구(control)와 대비하여 8배 증가하였으며, PPAR-γ의 경우에는, 후박 추출물을 100㎍/㎖ 처리한 세포에서 PPAR-γ 단백질의 발현이 89% 감소하는 것을 확인할 수 있었다. As a result of measuring the effect of the pear extract on the expression of PPAR-γ and HSL protein (FIGS. 4 and 5), as the concentration of the extract was increased, the protein expression of the HSL increased 8-fold compared to the control (PPAR). In the case of -γ, it was confirmed that the expression of PPAR-γ protein was reduced by 89% in cells treated with 100 μg / ml of the extract.
상기의 결과로부터 본 발명의 지방축적 억제용 화장료 조성물은 세포의 지방 분화 촉진과 관련된 단백질 발현을 억제하고 지방 분해 효소의 단백질 발현을 증가시킴으로써 실질적인 지방축적 억제효과를 발휘함을 추론할 수 있었다. From the above results, it can be inferred that the cosmetic composition for inhibiting fat accumulation of the present invention exhibits substantial fat accumulation inhibitory effect by inhibiting protein expression associated with promoting cell differentiation and increasing protein expression of lipase.
실험예Experimental Example 5: 5: 후박 추출물이 Thick Extract 렙틴Leptin (( LeptinLeptin ), ), PPARPPAR -α 및 -α and 리포프로테인Lipoprotein 리파아제 (Lipoprotein Lipase lipaselipase ) ) mRNAmRNA 발현에 미치는 영향 측정 Measure impact on expression
본 실험예 5에서는 후박 추출물이 렙틴(Leptin), PPAR-α 및 리포프로테인 리파아제(Lipoprotein lipase) mRNA 발현에 미치는 영향 측정하였다.In Experimental Example 5, the effect of the extract was extracted on leptin, PPAR-α and lipoprotein lipase mRNA expression.
RNA의 추출은 AGPC(Acid Guanidinium-Phenol-Chloroform) 법에 의한 총 RNA(total RNA) 추출시약(RNAiso Plus, TaKaRa, Japan)을 사용하였다. cDNA 합성은 'Transcriptor First Strand cDNA synthesis kit(Roche, Germany)'를 이용하여 cDNA를 합성하였으며, 'High Fidelity PCR Master(Roche, Germany)'와 제작된 프플프라이머(primer)를 사용하여 PCR을 수행하였다. cDNA 합성은 1㎍의 총 RNA(total RNA)로 50℃에서 1시간, 85℃에서 5분 동안 열을 가해줌으로써 반응을 중지시켰다. PCR 증폭은 94℃에서 50초 동안 변성(denaturation) 시키고 55℃에서 50초 동안 어닐링(annealing), 72℃에서 50초 동안 익스텐션(extension)시켰다. 이를 30 싸이클(cycle) 반복하였으며 'final extension'은 72℃에서 5분간 수행하였고, 증폭된 결과물은 2% 아가로스 겔(agarose gel)에서 전기영동하여 유전자 발현을 'chemiluminescent detection system(ChemiDoc XRS system, Bio-Rad Laboratories. USA)'로 확인하였다. 렙틴(Leptin), PPAR-α, 리포프로테인 리파아제(lipoprotein lipase; LPL)의 올리고뉴크레오티드(oligonucleotide) 서열은 다음과 같다.RNA was extracted using total RNA extract reagent (RNAiso Plus, TaKaRa, Japan) by AGPC (Acid Guanidinium-Phenol-Chloroform) method. cDNA synthesis was carried out using 'Transcriptor First Strand cDNA synthesis kit (Roche, Germany)' and cDNA was synthesized using 'High Fidelity PCR Master (Roche, Germany)' and the prepared primer (primer). . cDNA synthesis was stopped by heating 1 μg total RNA for 1 hour at 50 ° C. and 5 minutes at 85 ° C. PCR amplification was denatured at 94 ° C. for 50 seconds, annealed at 55 ° C. for 50 seconds, and extended at 72 ° C. for 50 seconds. This cycle was repeated for 30 cycles and the 'final extension' was performed at 72 ° C. for 5 minutes, and the amplified result was electrophoresed on a 2% agarose gel to express the genes in a 'chemiluminescent detection system (ChemiDoc XRS system, Bio-Rad Laboratories. USA). The oligonucleotide sequences of leptin, PPAR-α, lipoprotein lipase (LPL) are as follows.
leptin: sense; 5’-GGAATTC A GGAAAATGTGCTGGAG-3’, antisense; 5’-GGAATTCTCAGCATTCAGGGCT AAC -3’, leptin: sense; 5'-GGAATTC A GGAAAATGTGCTGGAG-3 ', antisense; 5'-GGAATTCTCAGCATTCAGGGCT AAC -3 ',
PPAR-α: sense; 5’-CCTGTCTGTCGGGATGTCACACAATGC-3’, antisense; 5’-GCAACTTCTCAATGTAGCCTATGTTT-3’PPAR-α: sense; 5'-CCTGTCTGTCGGGATGTCACACAATGC-3 ', antisense; 5’-GCAACTTCTCAATGTAGCCTATGTTT-3 ’
LPL: sense; 5’-GG CCGCAGCAGA CGCAGGAAGAGATTT-3’, antisense; 5’-AAGAAGGAGTAGGT TTTATTTGTGGA A-3’ LPL: sense; 5'-GG CCGCAGCAGA CGCAGGAAGAGATTT-3 ', antisense; 5'-AAGAAGGAGTAGGT TTTATTTGTGGA A-3 '
GAPDH: sense; 5’- AAATTCAACGGCACAGTCAA -3’, antisense; 5’- GTCTTCTGGGTGGCAGTGAT -3’GAPDH: sense; 5'- AAATTCAACGGCACAGTCAA -3 ', antisense; 5’- GTCTTCTGGGTGGCAGTGAT -3 ’
그 결과(도 6 내지 도 8), 도 6에서는 지방전구세포에서의 유전자 발현 정도를 측정할 수 있었는데, 지방 세포로의 분화에 관여하는 유전자인 PPAR-α와 렙틴(leptin), LPL의 발현 증가하는 것을 확인할 수 있었고 이것으로부터 지방 세포로의 분화가 일어났음을 확인할 수 있었다.As a result (Fig. 6 to Fig. 8), in Figure 6 it was possible to measure the gene expression level in the fat precursor cells, the expression of PPAR-α, leptin (Lptin), LPL genes involved in differentiation into adipocytes increased From this, it was confirmed that differentiation into fat cells occurred.
그리고 지방세포로의 분화 후, 후박 추출물 처리에 대한 유전자 발현을 측정한 결과(도 7 내지 도 8), PPAR-α와 렙틴(leptin), LPL의 유전자 발현이 억제되는 것을 확인할 수 있었다. After the differentiation into adipocytes, the gene expression of the thick extract extract treatment was measured (FIGS. 7 to 8), and it was confirmed that gene expression of PPAR-α, leptin, and LPL was suppressed.
상기의 결과로부터 본 발명의 지방축적 억제용 화장료 조성물은 지방세포로의 분화에 관여하는 유전자들의 발현을 억제함으로써 지방이 생성되는 것을 억제할 수 있다는 사실을 추론할 수 있었다.From the above results, it can be inferred that the cosmetic composition for inhibiting fat accumulation of the present invention can suppress the production of fat by inhibiting the expression of genes involved in differentiation into adipocytes.
도 1은 후박 추출물에 의한 'Human keratinocyte(HaCaT)'와 지방 전구세포인 3T3-L1(mouse embryonic fibroblast, preadipocyte)의 세포 생존률을 나타낸 도이다.1 is a diagram showing the cell survival rate of 'Human keratinocyte (HaCaT)' and fat progenitor cells 3T3-L1 (mouse embryonic fibroblast, preadipocyte) by the extract.
도 2는 후박 추출물의 처리시 3T3-L1 세포 내에 형성되는 지방의 축적 정도를 나타낸 도이다.Figure 2 is a diagram showing the degree of accumulation of fat formed in 3T3-L1 cells during the treatment of hakbak extract.
도 3은 후박 추출물의 처리시 3T3-L1 세포 내 트리글리세라이드(TG) 함량을 나타낸 도이다.Figure 3 is a diagram showing the triglyceride (TG) content in 3T3-L1 cells when the treatment of the extract.
도 4는 후박 추출물의 처리시 3T3-L1 세포 내 PPAR-γ 및 HSL 단백질 발현을 전기영동을 한 도이다.Figure 4 is a diagram showing the electrophoresis of PPAR-γ and HSL protein expression in 3T3-L1 cells during the treatment of hakbak extract.
도 5는 후박 추출물의 처리시 3T3-L1 세포 내 PPAR-γ 및 HSL 단백질 발현을 나타낸 도이다.Figure 5 is a diagram showing the expression of PPAR-γ and HSL protein in 3T3-L1 cells when the treatment of the extract.
도 6은 후박 추출물에 의한 지방전구세포에서 렙틴(Leptin), PPAR-α 및 리포프로테인 리파아제 (Lipoprotein lipase) mRNA 발현을 나타낸 도이다.Figure 6 is a diagram showing the expression of leptin (Leptin), PPAR-α and lipoprotein lipase (Lipoprotein lipase) mRNA in the fat precursor cells by the extract.
도 7과 도 8은 후박 추출물에 의한 지방세포로 분화 후 렙틴(Leptin), PPAR-α 및 리포프로테인 리파아제(Lipoprotein lipase) mRNA 발현을 나타낸 도이다. Figure 7 and Figure 8 is a diagram showing the expression of leptin (Leptin), PPAR-α and lipoprotein lipase (Lipoprotein lipase) mRNA after differentiation into adipocytes by hoobak extract.
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090044589A KR101127166B1 (en) | 2009-05-21 | 2009-05-21 | Cosmetic composition containing extract of Magnolia officinalis for reducing accumulation of lipid |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090044589A KR101127166B1 (en) | 2009-05-21 | 2009-05-21 | Cosmetic composition containing extract of Magnolia officinalis for reducing accumulation of lipid |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100125742A true KR20100125742A (en) | 2010-12-01 |
KR101127166B1 KR101127166B1 (en) | 2012-03-20 |
Family
ID=43503805
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090044589A KR101127166B1 (en) | 2009-05-21 | 2009-05-21 | Cosmetic composition containing extract of Magnolia officinalis for reducing accumulation of lipid |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101127166B1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101501380B1 (en) * | 2013-10-22 | 2015-03-10 | 동의대학교 산학협력단 | A composition comprising Euptelea Pleiosperma extracts having anti-obesity activity |
KR20210077664A (en) * | 2019-08-29 | 2021-06-25 | 재단법인대구경북과학기술원 | A composition comprising materials of inhibiting fgf11 for preventing and treating metabolic disease |
WO2023153815A1 (en) * | 2022-02-09 | 2023-08-17 | (주)보인바이오컨버젼스 | Composition for lipolysis comprising extract of morus alba l. bark and magnolia officinalis bark as active ingredient |
KR102705887B1 (en) * | 2023-08-22 | 2024-09-13 | 유승민 | Injection composition for lipolysis, slimming cosmetic composition and management method after lipolysis treatment using the same |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090025638A (en) * | 2007-09-06 | 2009-03-11 | 주식회사 디에이치피코리아 | Compositions for treatment and preventing obesity |
-
2009
- 2009-05-21 KR KR1020090044589A patent/KR101127166B1/en active IP Right Grant
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101501380B1 (en) * | 2013-10-22 | 2015-03-10 | 동의대학교 산학협력단 | A composition comprising Euptelea Pleiosperma extracts having anti-obesity activity |
KR20210077664A (en) * | 2019-08-29 | 2021-06-25 | 재단법인대구경북과학기술원 | A composition comprising materials of inhibiting fgf11 for preventing and treating metabolic disease |
WO2023153815A1 (en) * | 2022-02-09 | 2023-08-17 | (주)보인바이오컨버젼스 | Composition for lipolysis comprising extract of morus alba l. bark and magnolia officinalis bark as active ingredient |
KR102705887B1 (en) * | 2023-08-22 | 2024-09-13 | 유승민 | Injection composition for lipolysis, slimming cosmetic composition and management method after lipolysis treatment using the same |
Also Published As
Publication number | Publication date |
---|---|
KR101127166B1 (en) | 2012-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3272329B1 (en) | Compositions and methods for stimulation magp-1 to improve the appearance of skin | |
KR102105532B1 (en) | Method for derivation of inducible Pluripotent stem cells and inducible Pluripotent stem cells produced using the same | |
KR20210144835A (en) | composition for skin | |
KR101127166B1 (en) | Cosmetic composition containing extract of Magnolia officinalis for reducing accumulation of lipid | |
JP5858561B2 (en) | Preparations or cosmetics or cosmetics for hair or scalp, comprising moth-derived VEGF production promoter and moth-derived VEGF production promoter | |
JP5697879B2 (en) | Heat shock protein expression inducer | |
JP6539932B2 (en) | Composition for promoting expression of PPARγ containing black ginger | |
WO2012081370A1 (en) | Inhibitor of activity of endothelin, and skin whitening agent | |
KR20180082055A (en) | A functional cosmetic composition comprising ilex paraguariensis leaf extract | |
JP2013071901A (en) | Cosmetic for inhibiting melanin production | |
KR101167589B1 (en) | Anti-inflammatory agent containing stauntonia hexaphylla fruit extract | |
KR20150136857A (en) | Cosmetic composition comprising allergen removed water soluble royal jelly for skin whitening and anti-aging activity | |
KR101389970B1 (en) | A composition comprising ponciri fructus showing lipogenic effect | |
KR101774701B1 (en) | Skate Collagen Peptides With Activity Of Anti-Obesity | |
Chularojmontri et al. | Inhibitory Effect of Carallia Brachiata Extract Through Regulation of Adipogenesis Pathways in 3T3-L1 Cells | |
WO2016173867A1 (en) | Cosmetic use of extracts derived from somatic embryo enriched plant cell cultures and cosmetic compositions containing those extracts | |
KR20170076206A (en) | Composition comprising extract of Ilex cornuta for promoting the differentiation to adipocytic cells | |
JP2010150294A (en) | S100a8 expression regulator | |
JP2009242333A (en) | Peroxisome proliferator activated receptor-activator, and skin care preparation for external use, cosmetic, quasi-drug and food and drink comprising the peroxisome proliferator activated receptor-activator | |
KR20180078433A (en) | Anti-obesity composition comprising yomena aster extract | |
CN110711158A (en) | Cosmetic composition containing ilex extract for reducing sebum secretion and shrinking pore size | |
KR102333175B1 (en) | Anti-dark circle composition comprising Scutellaria baicalensis extract | |
KR101185903B1 (en) | Anti-inflammatory agent containing eupatorium japonicum extract | |
KR101330190B1 (en) | Cosmetic composition for inhibits adipogenesis of Prunella vulgaris extract via modulated HO-1 expression | |
CN102209536A (en) | Skin external composition for inhibiting epidermal hyperproliferation and alleviating inflammatory skin diseases containing ortho-dihydroxyisoflavone derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20141226 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20160304 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20170303 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20171222 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20181211 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20191209 Year of fee payment: 9 |